Alnylam Pharmaceuticals, Inc. (ALNY)
| Market Cap | 52.92B |
| Revenue (ttm) | 3.21B |
| Net Income (ttm) | 43.57M |
| Shares Out | 132.11M |
| EPS (ttm) | 0.33 |
| PE Ratio | 1,214.82 |
| Forward PE | 60.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 401,419 |
| Open | 404.58 |
| Previous Close | 400.69 |
| Day's Range | 397.31 - 404.58 |
| 52-Week Range | 205.87 - 495.55 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 479.45 (+19.69%) |
| Earnings Date | Feb 12, 2026 |
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price target is $479.45, which is an increase of 19.69% from the latest price.
News
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing faci...
Is Alnylam Entering A Corrective Phase After A Strong Run?
Alnylam (NASDAQ: ALNY) has corrected by roughly 13% over the past couple of weeks. To understand why this pullback is unfolding now, it is important to examine the stock's structure through the lens o...
Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut
Six companies will join the Nasdaq-100 later this month — but not Walmart, which switched its listing away from the New York Stock Exchange too late to qualify for a spot in the tech-heavy index.
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotia...
Alnylam Pharmaceuticals Announces Changes to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of tw...
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing
Those four companies, culled from a list drawn up by KBW analyst Shreyank Gandhi, are among the largest not in the index.
American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Chipotle Mexican Grill reported mixed quarte...
What's Going On With Alnylam Stock On Friday?
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement.
Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review
The Virtus Silvant Mid-Cap Growth Fund returned +5.43% (Class INST) for the quarter, compared to the Russell Midcap Growth Index's return of +2.78%. Palantir Technologies (PLTR) and Roblox (RBLX) were...
UK's drug-cost watchdog recommends Alnylam's heart disease drug
The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, ensuring access for patients through the government health system in England and Wales, the compa...
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Alnylam Pharmaceuticals, Inc. ( ALNY) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP ...
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript
Alnylam Pharmaceuticals, Inc. ( ALNY) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President ...
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study...
American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive p...
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak
Alnylam Pharmaceuticals, Inc. delivered strong Q3 results, driven by Amvuttra's success in ATTR-CM, with total revenues soaring to $1.25 billion. ALNY's market cap surged to $59B as Amvuttra outperfor...
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. ( ALNY) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - CEO & ...
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) stock is trading lower after the company reported third-quarter earnings.
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se...
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi...
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN Car...
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUT...